Q2 2026 BioMarin Pharmaceutical Inc Earnings Call Transcript
Key Points
- BioMarin Pharmaceutical Inc (BMRN) delivered a standout second quarter with 20% year-over-year total revenue growth, reaching nearly $1 billion in revenue.
- The company successfully closed and integrated the Amicus acquisition, with Galafold and PomBility/Opfolda showing strong pro forma growth of approximately 10% and over 65% year-over-year, respectively.
- VOXZOGO demonstrated resilience despite a new US competitor, with 90% of US patients remaining on therapy and double-digit revenue growth, leading to increased full-year guidance and a path to become BioMarin's first $1 billion product.
- The company identified significant cost synergies of approximately $220 million annual run rate by 2028, expected to drive substantial EPS accretion and operating cash flow, with deleveraging accelerated by about one year.
- Pipeline momentum is strong, highlighted by the rapid SNDA submission for VOXZOGO in hypochondroplasia (79 days from database lock to filing) and the addition of BMN 820, a late-stage asset for FSGS with a favorable safety profile.
- The company raised full-year 2026 guidance for total revenues, VOXZOGO revenue, and non-GAAP diluted EPS, reflecting strong first-half performance and confidence in the second half.
- Galafold and PomBility/Opfolda have substantial peak revenue potential of $1.4 billion and $1.2 billion, respectively, supported by strategies to expand diagnosis, treatment, and global market penetration.
- Non-GAAP diluted EPS decreased year-over-year due to higher operating expenses from the Amicus acquisition, increased interest expense from acquisition debt financing, and lower interest income.
- The company faces competitive pressure in the US for VOXZOGO, with approximately 10% of US patients switching to the competitor product since its launch, and the full impact on future market share remains uncertain.
- The Amicus acquisition is expected to be modestly dilutive to non-GAAP EPS in 2026, with substantial accretion only beginning in 2027 and full synergies realized in 2028.
- Interest expense from acquisition debt financing is estimated at approximately $200 million annually, which will continue to weigh on non-GAAP EPS in the near term.
- The company faces ongoing legal and regulatory uncertainties, including the ITC case related to VOXZOGO patents, with a final decision expected in December 2026 and potential exclusion orders.
- Revenue in the metabolic conditions portfolio is subject to quarterly order timing fluctuations, which can create volatility in individual product revenues, as seen with Vimizim and Naglazyme.
- The company's growth plans for Galafold and PomBility/Opfolda rely on improving diagnosis rates and patient switching, which have historically been challenging in rare diseases like Fabry and Pompe, and may not materialize as quickly as projected.
Good afternoon and welcome everyone to the BioMarin Pharmaceutical Second Quarter 2026 Conference Call. Today's conference is being recorded.
All lines have been placed on mute to forget any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press the star key followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again.
At this time, I would like to turn the conference over to Tracy McCarty, Head of Investor Relations.
Thank you, Operator, and thank you all for joining us today. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products, and potential future products in different areas of therapeutic research and development.
Results may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
